| Inflammasome signaling affects anxiety-and depressive-like behavior and gut microbiome composition ML Wong, A Inserra, MD Lewis, CA Mastronardi, LEX Leong, J Choo, ... Molecular psychiatry 21 (6), 797-805, 2016 | 556 | 2016 |
| Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms A Inserra, D De Gregorio, G Gobbi, M Nader Pharmacological Reviews 73 (1), 202-277, 2021 | 191 | 2021 |
| The microbiota‐inflammasome hypothesis of major depression A Inserra, GB Rogers, J Licinio, ML Wong Bioessays 40 (9), 1800027, 2018 | 142 | 2018 |
| Hypothesis: the psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process A Inserra Frontiers in pharmacology 9, 330, 2018 | 115 | 2018 |
| Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission D De Gregorio, J Popic, JP Enns, A Inserra, A Skalecka, A Markopoulos, ... Proceedings of the National Academy of Sciences 118 (5), e2020705118, 2021 | 97 | 2021 |
| Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma A Inserra, CA Mastronardi, G Rogers, J Licinio, ML Wong Molecular neurobiology 56 (6), 4288-4305, 2019 | 90 | 2019 |
| Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline D De Gregorio, A Inserra, JP Enns, A Markopoulos, M Pileggi, ... Neuropsychopharmacology 47 (6), 1188-1198, 2022 | 66 | 2022 |
| Ceremonial ayahuasca in amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study SGD Ruffell, N Netzband, WF Tsang, M Davies, A Inserra, M Butler, ... Frontiers in psychiatry 12, 687615, 2021 | 57 | 2021 |
| Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder A Markopoulos, A Inserra, D De Gregorio, G Gobbi Frontiers in Pharmacology 12, 749068, 2022 | 35 | 2022 |
| Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice A Inserra, D De Gregorio, T Rezai, MG Lopez-Canul, S Comai, G Gobbi Journal of Psychopharmacology 35 (4), 469-482, 2021 | 34 | 2021 |
| Chronic stress induces hypersensitivity of murine gastric vagal afferents H Li, FTA Buisman‐Pijlman, M Nunez‐Salces, S Christie, CL Frisby, ... Neurogastroenterology & Motility 31 (12), e13669, 2019 | 29 | 2019 |
| Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): impact on neurotropic … A Inserra, A Campanale, D Cheishvili, S Dymov, A Wong, N Marcal, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 119, 110594, 2022 | 26 | 2022 |
| Current status of psychedelic therapy in Australia and New Zealand: Are we falling behind? A Inserra Australian & New Zealand Journal of Psychiatry 53 (3), 190-192, 2019 | 24 | 2019 |
| Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome A Inserra, G Giorgini, S Lacroix, A Bertazzo, J Choo, A Markopolous, ... British Journal of Pharmacology 180 (6), 721-739, 2023 | 21 | 2023 |
| Mice lacking Casp1, Ifngr and Nos2 genes exhibit altered depressive- and anxiety-like behaviour, and gut microbiome composition A Inserra, JM Choo, MD Lewis, GB Rogers, ML Wong, J Licinio Scientific reports 9 (1), 6456, 2019 | 20 | 2019 |
| Molecular pathways involved in the improvement of non-alcoholic fatty liver disease G Paz-Filho, CA Mastronardi, BJ Parker, A Khan, A Inserra, KI Matthaei, ... J Mol Endocrinol 51 (1), 167-179, 2013 | 20 | 2013 |
| The central role of the Thalamus in psychosis, lessons from neurodegenerative diseases and psychedelics M Onofrj, M Russo, S Delli Pizzi, D De Gregorio, A Inserra, G Gobbi, ... Translational Psychiatry 13 (1), 384, 2023 | 16 | 2023 |
| Lysergic Acid Diethylamide (LSD) for the treatment of anxiety disorders: preclinical and clinical evidence A Inserra, A Piot, D De Gregorio, G Gobbi CNS drugs 37 (9), 733-754, 2023 | 10 | 2023 |
| Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice G Gobbi, A Inserra, KT Greenway, M Lifshitz, LJ Kirmayer Transcultural Psychiatry 59 (5), 718-724, 2022 | 7 | 2022 |
| Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics A Campanale, A Inserra, S Comai Progress in Neuro-Psychopharmacology and Biological Psychiatry, 111058, 2024 | 5 | 2024 |
